ATE243998T1 - Liposomformulierung von 5-beta steroiden - Google Patents

Liposomformulierung von 5-beta steroiden

Info

Publication number
ATE243998T1
ATE243998T1 AT96933929T AT96933929T ATE243998T1 AT E243998 T1 ATE243998 T1 AT E243998T1 AT 96933929 T AT96933929 T AT 96933929T AT 96933929 T AT96933929 T AT 96933929T AT E243998 T1 ATE243998 T1 AT E243998T1
Authority
AT
Austria
Prior art keywords
liposome formulation
5beta
dhea
steroid
lipid
Prior art date
Application number
AT96933929T
Other languages
English (en)
Inventor
Joseph Rubinfeld
Elliott L Fineman
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Application granted granted Critical
Publication of ATE243998T1 publication Critical patent/ATE243998T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT96933929T 1995-10-12 1996-09-27 Liposomformulierung von 5-beta steroiden ATE243998T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54208395A 1995-10-12 1995-10-12
PCT/US1996/015507 WO1997013500A2 (en) 1995-10-12 1996-09-27 LIPOSOME FORMULATIONS OF 5β STEROIDS

Publications (1)

Publication Number Publication Date
ATE243998T1 true ATE243998T1 (de) 2003-07-15

Family

ID=24162270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933929T ATE243998T1 (de) 1995-10-12 1996-09-27 Liposomformulierung von 5-beta steroiden

Country Status (10)

Country Link
US (1) US6436435B1 (de)
EP (1) EP0801557B1 (de)
JP (1) JPH10508322A (de)
CN (1) CN1173815A (de)
AT (1) ATE243998T1 (de)
CA (1) CA2208215A1 (de)
DE (1) DE69628909T2 (de)
HU (1) HUP9801834A3 (de)
IL (1) IL121070A (de)
WO (1) WO1997013500A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CA2669753C (en) * 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
FR2799645B1 (fr) 1999-10-13 2004-04-30 Oreal Utilisation de la dhea ou de ses precurseurs ou derives metaboliques comme depigmentant
ATE413179T1 (de) * 1999-10-25 2008-11-15 Hollis Eden Pharmaceuticals Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
FR2807323A1 (fr) 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
AU2002244247B2 (en) * 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
WO2003009811A2 (en) * 2001-07-25 2003-02-06 Haase Richard A Processes and apparatus for the manufacture of polynuclear aluminum compounds and disinfectants, and polynuclear aluminum compounds and disinfectants from such processes and apparatus
FR2827766A1 (fr) * 2001-07-27 2003-01-31 Oreal Composition a base de vesicules lamellaires lipidiques incorporant au moins un compose a base de dhea
FR2827765B1 (fr) * 2001-07-27 2003-09-19 Oreal Composition a base de vesicules lamellaires lipidiques incorporant au moins un compose a base de dhea
US20040034003A1 (en) * 2002-05-01 2004-02-19 Schwartz Arthur G. 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8268269B2 (en) 2006-01-24 2012-09-18 Clearvalue Technologies, Inc. Manufacture of water chemistries
ATE544759T1 (de) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
AU2008326309C1 (en) 2007-11-21 2015-03-12 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
KR20150116466A (ko) 2009-01-26 2015-10-15 이스라엘 인스티튜트 포 바이올로지컬 리서치 이환형 헤테로사이클릭 스피로 화합물
AU2010273732A1 (en) 2009-07-14 2012-02-09 Albany Molecular Research, Inc. 5-HT3 receptor modulators, methods of making, and use thereof
EP2569000B1 (de) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon-superfamilien-peptide mit nuklearhormon-rezeptoraktivität
PL2575768T3 (pl) 2010-05-24 2018-07-31 Swedish Oat Fiber Ab Wodna dyspersja zawierająca galaktolipidy oraz sposób jej wytwarzania
EP2588126A4 (de) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp Amidbasierte glucagon-superfamilien-peptid-prodrugs
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2022515652A (ja) 2018-12-31 2022-02-21 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4518595A (en) 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
FR2551758B1 (fr) * 1983-08-16 1986-01-31 Anvar Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
US4666898A (en) 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
US4507289A (en) 1983-12-28 1985-03-26 Progenics, Inc. Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
CA1264668C (en) 1984-06-20 1990-01-23 EXTRUSION TECHNIQUES FOR THE PRODUCTION OF LIPOSOMES
DE3689769T2 (de) 1985-07-05 1994-07-21 Liposome Co Inc Multilamellare liposome mit verbesserter einschliessungswirkung.
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
DE3626421A1 (de) * 1986-08-05 1988-02-11 Recipe Pharma Vertriebs Gmbh & Peptid, pharmazeutisches mittel und verwendung desselben zur stimulierung der lipolyse
US5006517A (en) 1987-12-01 1991-04-09 Progenics, Inc. Treatment of Prader-Willi syndrome
US5041287A (en) 1989-05-22 1991-08-20 Terry L. Driggers Sprayable composition using acetone solvent
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU668934B2 (en) 1992-04-10 1996-05-23 Hisamitsu Pharmaceutical Co., Inc. Liposome composition
WO1994004155A1 (en) * 1992-08-19 1994-03-03 Health Resource Institute, Ltd. Dehydroepiandrosterone therapy for the treatment of eye disorders
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen

Also Published As

Publication number Publication date
HUP9801834A3 (en) 2000-06-28
DE69628909D1 (de) 2003-08-07
DE69628909T2 (de) 2003-12-24
IL121070A (en) 2004-06-20
CN1173815A (zh) 1998-02-18
HUP9801834A2 (hu) 1999-02-01
CA2208215A1 (en) 1997-04-17
US6436435B1 (en) 2002-08-20
JPH10508322A (ja) 1998-08-18
EP0801557B1 (de) 2003-07-02
WO1997013500A2 (en) 1997-04-17
EP0801557A2 (de) 1997-10-22
IL121070A0 (en) 1997-11-20
WO1997013500A3 (en) 1997-05-29

Similar Documents

Publication Publication Date Title
ATE243998T1 (de) Liposomformulierung von 5-beta steroiden
NO980277L (no) Hormonplaster
NL193616B (nl) Gesubstitueerde androsta-1,4-dieen-3,17-dionen, alsmede farmaceutische preparaten die dergelijke verbindingen bevatten.
PT1090029E (pt) 14,15-ciclopropanoesteroides da serie dos 19-norandrostanos, processo para a sua producao e preparacoes farmaceuticas contendo estes compostos
NO20030961L (no) Farmasöytiske preparater samt metode for behandling av hypogonadisme
DE122007000006I1 (de) Hautpflaster enthaltend Testosteron und gegebenenfalls Estrogen
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
NL300109I1 (nl) Kristalmodificatie van CDCH, werkwijze voor de bereiding ervan en van farmaceutische preparaten die deze modificaties bevatten.
EA200000711A1 (ru) 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, СПОСОБ ПОЛУЧЕНИЯ ФАРМАЦЕВТИЧЕСКИХ ПРЕПАРАТОВ, СОДЕРЖАЩИХ ЭТИ 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, И ИХ ПРИМЕНЕНИЕ ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
AU7072596A (en) Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
NO20065784L (no) Steroidforbindelser og anvendelse av slike
CA2069483A1 (en) Steroid sulphatase inhibitors
IE831226L (en) Method for preparing 26,26,26,27,27,27-hexafluoro-1ó,25-¹dihydrocholestrol
AU4101589A (en) Pharmaceutical preparations which can be applied transdermally, containing sterolins and/or spiroketalins
PT99435A (pt) Processo para a preparacao de derivados de amino-sulfonil-ureia e de composicoes farmaceuticas que os contem
DE59608150D1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
Mitsuhiro et al. Induction of peroxisomal β-oxidation by structural analogues of dehydroepiandrosterone in cultured rat hepatocytes: structure-activity relationships
ATE183512T1 (de) Kardioaktive 17-hydroxyiminoalkyl- und 17- hydroxyiminomethylalkenyl-steroid-derivate, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon
FI873489A7 (fi) Menetelmä 4-androsteeni-3,17-dionin ja 1,4-androstadieeni-3,17-dionin valmistamiseksi.
ATE240343T1 (de) Darstellung von esterderivaten von steroiden
EP1210874A4 (de) "knockout"-tier für das alpha-tocopherol-transportprotein
FI946082A0 (fi) Menetelmä steroidisten perasyyliglykosidien valmistamiseksi
LV10902A (lv) Metode holesterina un ta metabolitu izdalisanai no biologiskiem audiem
BR9814717A (pt) "método de preparação de esteróides 16alfa, 17alfa-dialquilados"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties